About | Free Trial

Last Update

2016-08-23T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong Mary Fitzgerald?

Dr. Mary Fitzgerald F.

Vice President - Clinical

Pulmagen Therapeutics Limited

Direct Phone: +44 **********       

Email: m***@***.com

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Company Description

Pulmagen Therapeutics is a privately held respiratory drug development company headquartered in Burnham, Bucks, UK. The company has developed a portfolio of clinical programmes targeting chronic respiratory diseases including severe persistent asthma, a ... more

Find other employees at this company (4)

Background Information

Employment History

Vice President of Respiratory Medicine

Pieris Pharmaceuticals Inc

Cso

Calcico Therapeutics Limited

Head of Pharmacology

Bayer HealthCare AG

Vice President Respiratory Medicine

Pieris AG

Head of Pharmacology

Argenta Discovery Limited

Head of Pharmacology and Respiratory Project Leader

Bayer AG

Education

BSc

Pharmacology

Bath University

Ph.D.

PhD

Sunderland University

Web References (41 Total References)


Management Team :: Pieris Pharmaceuticals, Inc. (PIRS)

www.pieris.com [cached]

Mary Fitzgerald, Ph.D.

...
Mary Fitzgerald, Ph.D.
Vice President of Respiratory Medicine
Dr. Mary Fitzgerald brings to Pieris more than thirty years of respiratory drug development experience. Prior to joining Pieris, Dr. Fitzgerald, from February 2010 was the Executive Vice President of Respiratory at Pulmagen Therapeutics and from November 2002 to February 2010, Dr. Fitzgerald held various positions at Etiologics, Ltd., formerly Argenta Discovery, most recently as Executive Vice President of Respiratory, where she was responsible for clinical development of inhaled and oral drug candidates for both COPD and asthma. Previously, from 1988 to 2002 Dr. Fitzgerald was employed by Bayer Healthcare, as a Project Leader and later as Head of Pharmacology. Dr. Fitzgerald received her PhD from Sunderland University / Wellcome Laboratories and received her BSc Pharmacology from Bath University.


Management Team :: Pieris Pharmaceuticals, Inc. (PIRS)

ir.pieris.com [cached]

Mary Fitzgerald, Ph.D.

...
Mary Fitzgerald, Ph.D.
Vice President of Respiratory Medicine
Dr. Mary Fitzgerald brings to Pieris more than thirty years of respiratory drug development experience. Prior to joining Pieris, Dr. Fitzgerald, from February 2010 was the Executive Vice President of Respiratory at Pulmagen Therapeutics and from November 2002 to February 2010, Dr. Fitzgerald held various positions at Etiologics, Ltd., formerly Argenta Discovery, most recently as Executive Vice President of Respiratory, where she was responsible for clinical development of inhaled and oral drug candidates for both COPD and asthma. Previously, from 1988 to 2002 Dr. Fitzgerald was employed by Bayer Healthcare, as a Project Leader and later as Head of Pharmacology. Dr. Fitzgerald received her PhD from Sunderland University / Wellcome Laboratories and received her BSc Pharmacology from Bath University.


Mary Fitzgerald, Executive ...

www.smi-online.co.uk [cached]

Mary Fitzgerald, Executive VP Respiratory, Pulmagen

Mary Fitzgerald, PhD, is the Executive Vice President of Respiratory at Pulmagen Therapeutics, where she leads a multi-disciplinary team that specializes in pre-clinical safety, regulatory affairs, CMC and clinical operations. Dr Fitzgerald has been an Executive Director of Argenta/Pulmagen since 2004. She was also responsible for clinical development at Argenta from 2008 to 2010. Previously, Dr. Fitzgerald was with Bayer HealthCare for 14 years, latterly as Head of Pharmacology. She was also the Head of Pharmacology at Argenta for 6 years with responsibility for establishing disease relevant models of chronic respiratory disease. She has spent over 20 years in the pharmaceutical industry and her major interest is in the development of anti-inflammatory therapies for COPD, asthma and cystic fibrosis. She is currently involved in 4 inhaled anti-inflammatory programmes for COPD, including three programmes with the potential to switch on ICS in COPD and severe asthma. She is also involved in the clinical development of an oral CRTh2 antagonist for asthma which is currently in Phase II.


Mary Fitzgerald, Executive ...

www.smi-online.co.uk [cached]

Mary Fitzgerald, Executive VP Respiratory, Pulmagen

Mary Fitzgerald, PhD, is the Executive Vice President of Respiratory at Pulmagen Therapeutics, where she leads a multi-disciplinary team that specializes in pre-clinical safety, regulatory affairs, CMC and clinical operations. Dr Fitzgerald has been an Executive Director of Argenta/Pulmagen since 2004. She was also responsible for clinical development at Argenta from 2008 to 2010. Previously, Dr. Fitzgerald was with Bayer HealthCare for 14 years, latterly as Head of Pharmacology. She was also the Head of Pharmacology at Argenta for 6 years with responsibility for establishing disease relevant models of chronic respiratory disease. She has spent over 20 years in the pharmaceutical industry and her major interest is in the development of anti-inflammatory therapies for COPD, asthma and cystic fibrosis. She is currently involved in 4 inhaled anti-inflammatory programmes for COPD, including three programmes with the potential to switch on ICS in COPD and severe asthma. She is also involved in the clinical development of an oral CRTh2 antagonist for asthma which is currently in Phase II.


Mary Fitzgerald, Executive ...

www.smi-online.co.uk [cached]

Mary Fitzgerald, Executive VP Respiratory, Pulmagen

Mary Fitzgerald, PhD, is the Executive Vice President of Respiratory at Pulmagen Therapeutics, where she leads a multi-disciplinary team that specializes in pre-clinical safety, regulatory affairs, CMC and clinical operations. Dr Fitzgerald has been an Executive Director of Argenta/Pulmagen since 2004. She was also responsible for clinical development at Argenta from 2008 to 2010. Previously, Dr. Fitzgerald was with Bayer HealthCare for 14 years, latterly as Head of Pharmacology. She was also the Head of Pharmacology at Argenta for 6 years with responsibility for establishing disease relevant models of chronic respiratory disease. She has spent over 20 years in the pharmaceutical industry and her major interest is in the development of anti-inflammatory therapies for COPD, asthma and cystic fibrosis. She is currently involved in 4 inhaled anti-inflammatory programmes for COPD, including three programmes with the potential to switch on ICS in COPD and severe asthma. She is also involved in the clinical development of an oral CRTh2 antagonist for asthma which is currently in Phase II.

Similar Profiles

Other People with this Name

Other people with the name Fitzgerald

Tracey Fitzgerald
Bay Property Services

Mercedes Fitzgerald
Re/max Allegiance

Patricia Fitzgerald
Saint Cecilia School

Darlene Fitzgerald
Tom A. Finch Community YMCA

David FitzGerald

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory